Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROTATE albuminuria drug-rotation crossover study in type 2 diabetes
NL-OMON26322Not yet recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of telmisartan, empagliflozin, linagliptin and sulodexide in type 2 diabetes mellitus (T2DM) and albuminuria (2 arms), sponsored by University Medical Center Groningen. Primary endpoint: Albuminuria reduction. Planned start Mar 2016; status: not yet recruiting.
02
Drugs
telmisartanempagliflozinlinagliptinsulodexide
03
Conditions
type 2 diabetes mellitus (T2DM)albuminuria
Beyond the preview
Go deeper on NL-OMON26322.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON26322.